We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences, Inc. (GILD) - free report >>
KT Corporation (KT) - free report >>
Extreme Networks, Inc. (EXTR) - free report >>
Image: Bigstock
New Strong Sell Stocks for February 10th
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Extreme Networks, Inc. (EXTR - Free Report) provides software-driven networking solutions for enterprise, data center, and service provider customers. The Zacks Consensus Estimate for its current year earnings has been revised 18.3% downward over the last 30 days.
Funko, Inc. (FNKO - Free Report) is a pop culture consumer products company, designs, sources, and distributes licensed pop culture products. The Zacks Consensus Estimate for its current year earnings has been revised 12.4% downward over the last 30 days.
Capri Holdings Limited (CPRI - Free Report) designs, markets, distributes, and retails branded women's and men's apparel and accessories. The Zacks Consensus Estimate for its current year earnings has been revised 7.6% downward over the last 30 days.
KT Corporation (KT - Free Report) provides telecommunications services. The Zacks Consensus Estimate for its current year earnings has been revised 7.2% downward over the last 30 days.
Gilead Sciences, Inc. (GILD - Free Report) a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs. The Zacks Consensus Estimate for its current year earnings has been revised nearly 7% downward over the last 30 days.
View the entire Zacks Rank #5 List.